Leon O. Moulder Jr. is CEO at Zenas BioPharma, Inc. (ZBIO). They have made 16 open-market trades across 5 companies since 2006, most recently 2026-06-17.
CIK 0001228865
16 open-market purchases totalling $9.6M since 2006, never a sale. Across 14 scored buys the stock is up 5.4% at ninety days, and 3.0 points ahead of the S&P over the same stretch.
14 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 50% | 50% |
| Avg Move | -0.8% | +5.7% | +5.4% |
| Alpha | -0.2% | +5.2% | +3.0% |
| Scored | 14 | 14 | 14 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZBIO | BUY | 2026-05-18 | 2026-05-18 | $16.88 | $1.0M | +4.8% | +5.8% | +73.8% |
| ZBIO | BUY | 2026-04-28 | 2026-04-29 | $17.79 | $1.1M | +7.6% | -3.1% | +69.9% |
| ZBIO | BUY | 2026-03-30 | 2026-03-31 | $18.91 | $1.0M | +3.3% | -5.0% | +25.3% |
| ZBIO | BUY | 2026-02-02 | 2026-02-03 | $17.96 | $1.0M | +24.5% | +19.1% | +1.5% |
| ZBIO | BUY | 2026-01-07 | 2026-01-09 | $16.39 | $1.6M | +18.4% | +30.4% | +23.5% |
| ZBIO | BUY | 2025-10-07 | 2025-10-09 | $20.85 | $1.5M | -11.1% | +10.9% | -43.6% |
| ZBIO | BUY | 2025-02-18 | 2025-02-19 | $6.67 | $167K | -2.4% | +22.5% | +68.8% |
| ZBIO | BUY | 2024-12-03 | 2024-12-04 | $10.26 | $718K | -18.4% | -8.6% | -35.5% |
| ZBIO | BUY | 2024-11-18 | 2024-11-20 | $14.89 | $149K | -16.5% | -22.1% | -48.2% |
| ZBIO | BUY | 2024-09-18 | 2024-09-20 | $18.04 | $361K | -4.5% | +19.7% | -49.7% |
| TRVN | BUY | 2019-02-01 | 2019-02-04 | $1.02 | $102K | +30.3% | +24.4% | +29.4% |
| TSRO | BUY | 2018-03-02 | 2018-03-05 | $56.93 | $285K | +7.7% | -4.4% | -29.3% |
| TRVN | BUY | 2014-12-09 | 2014-12-10 | $4.00 | $200K | -25.2% | -5.0% | -5.0% |
| TSRO | BUY | 2012-08-30 | 2012-08-31 | $11.69 | $117K | -30.2% | -4.9% | -4.9% |
| CBST | BUY | 2011-11-04 | 2011-11-08 | $36.78 | $184K | N/A | N/A | N/A |
| MOGN | BUY | 2006-08-04 | 2006-08-07 | $14.16 | $28K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| CBST |
| 9,997 |
| — |
| Total | $185.8M |
Shares reported on the most recent Form 4, priced at the 2026-06-22 close. 3 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.